Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study investigated the efficacy and safety of once-daily liraglutide 1.2 mg versus placebo as add-on to insulin treatment in normal-weight patients with poorly controlled type 1 diabetes. RESEARCH DESIGN AND METHODS: In a randomized (1:1), double-blind, placebo-controlled design, 40 patients with type 1 diabetes (HbA1c ≥8% [64 mmol/mol]) received once-daily liraglutide 1.2 mg or placebo for 12 weeks. Continuous glucose monitoring was performed before and at the end of treatment. The primary end point was change in HbA1c. Secondary end points included change in insulin dose, weight, glycemic excursions, heart rate, and blood pressure. RESULTS: Baseline HbA1c was similar in the liraglutide and placebo group (8.8 ± 0.2 and 8.7 ± 0.1% [72.5 ± 2.2 and 71.8 ± 1.5 mmol/mol]). Change in HbA1c from baseline was −0.6 ± 0.2% (−6.22 ± 1.71 mmol/mol) with liraglutide and −0.5 ± 0.2% (−5.56 ± 1.67 mmol/mol) with placebo (P = 0.62). Variation in glycemic excursions did not change in either group. Change in body weight was −3.13 ± 0.58 and +1.12 ± 0.42 kg (P < 0.0001) with liraglutide and placebo, respectively. The bolus insulin dose decreased in liraglutide-treated patients and did not change with placebo treatment (4.0 ± 1.3 vs. 0.0 ± 1.0 IU, P = 0.02). Heart rate increased within the liraglutide group (P = 0.04) but not compared with placebo, whereas mean systolic blood pressure decreased compared with placebo (between-group difference 3.21 mmHg [95% CI −8.31 to 1.90], P = 0.04). Liraglutide was more frequently associated with gastrointestinal adverse effects. The incidence of hypoglycemia did not differ between groups. CONCLUSIONS: Liraglutide significantly reduces body weight and insulin requirements but has no additional effect on HbA1c in normal-weight patients with type 1 diabetes inadequately controlled on insulin alone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While several studies included in their analysis did not find significant changes in HbA1c, they did find a reduction in insulin requirements.15,35,36”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [35]
In the citing paper
“ketoacidosis at lower glucose levels, so called 'euglycaemic ketoacidosis', has been reported in 2-3% of patients with T1DM taking SGLT2 inhibitors.804”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [804]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 1×
“requiring assistance of another person to actively administer carbohydrates, glucagon, or take other corrective actions with or without measurement of blood glucose levels (33).”
BackgroundPathologic anatomy of the pancreas in juvenile diabetes mellitus
Gepts, W. (1965) · Diabetes · doi:10.2337/diab.14.10.619 · Cited by 1,345
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Self-citationRisk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration
UK Hypoglycaemia Study Group (2007) · Diabetologia · doi:10.1007/s00125-007-0599-y · Cited by 825
Gold, A. E., Macleod, K. M., & Frier, B. M. (1994) · Diabetes Care · doi:10.2337/diacare.17.7.697 · Cited by 810 · cited 2×
“hypoglycemic awareness status was determined by the Gold (25), Clarke (26)”
MethodClarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Mathieu, C., Zinman, B., Hemmingsson, J. U., Woo, V., Colman, P., Christiansen, E., Linder, M., Bode, B., & for the ADJUNCT ONE Investigators (2016) · Diabetes Care · doi:10.2337/dc16-0691 · Cited by 347
“lower insulin dose in liraglutide-treated subjects, as well as difficulties in accurately adjusting bolus insulin and food intake (6,9).”
BackgroundAhrén, B., Hirsch, I. B., Pieber, T. R., Mathieu, C., Gómez-Peralta, F., Hansen, T. K., Philotheou, A., Birch, S., Christiansen, E., Jensen, T. J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0690 · Cited by 262
New frontiers in the treatment of type 1 diabetes
Warshauer, J. T., Bluestone, J. A., & Anderson, M. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.017 · Cited by 259
Alfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224
“15,35,36 Furthermore, differences in hypo-glycemic events were not substantial or reduced in combination treatment, suggesting that combination treatment does not increase the risk of hypoglycemia.”
BackgroundDejgaard, T. F., Frandsen, C. S., Hansen, T. S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., Jensen, T., Jensen, A. K., Holst, J. J., Tarnow, L., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00436-2 · Cited by 179
Self-citationCurrent and future therapies for type 1 diabetes
von Scholten, B. J., Kreiner, F. F., Gough, S. C. L., & von Herrath, M. (2021) · Diabetologia · doi:10.1007/s00125-021-05398-3 · Cited by 173
Therapies for Type 1 Diabetes: Current Scenario and Future Perspectives
Pathak, V., Pathak, N., O’Neill, C. L., Guduric‐Fuchs, J., & Medina, R. J. (2019) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551419844521 · Cited by 170
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116
Kuhadiya, N. D., Dhindsa, S., Ghanim, H., Mehta, A., Makdissi, A., Batra, M., Sandhu, S., Hejna, J., Green, K., Bellini, N., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1136 · Cited by 101
“8 mg liraglutide demonstrated significant reduction in body weight and insulin dose without any additional effect on HbA1c compared with placebo (14,15).”
BackgroundNon-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus
Frandsen, C. S., Dejgaard, T. F., & Madsbad, S. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00039-5 · Cited by 101
Self-citationGourgari, E., Wilhelm, E. E., Hassanzadeh, H., Aroda, V. R., & Shoulson, I. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.08.005 · Cited by 95
Dejgaard, T. F., Schmidt, S., Frandsen, C. S., Vistisen, D., Madsbad, S., Andersen, H. U., & Nørgaard, K. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13911 · Cited by 72
“2020;22:492–500.wileyonlinelibrary.com/journal/dom type 1 diabetes in the industrialized part of the world are overweight, and interventions to prevent weight gain are strongly warranted.1,2 Compared with multiple daily injections (MDI) subcutaneous insulin infusion (CSII) therapy improves glycaemic control and reduce…”
BackgroundMethodResultInfluentialSelf-citationWang, W., Liu, H., Xiao, S., Liu, S., Li, X., & Yu, P. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0282-3 · Cited by 70
“We excluded one study [14] based on the results of sensitivity analysis because the difference in baseline data between the experimental group and the control group interfered with the conclusion; this excluded paper’s Table 2 Forest plot showing the effect of combined glucagon-like peptide-1 receptor agonist (GLP-1RA…”
BackgroundMethodResultInfluentialPark, J., Ntelis, S., Yunasan, E., Downton, K. D., Yip, T. C.-F., Munir, K. M., & Haq, N. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad471 · Cited by 69
Kong, F., Wu, J., Sun, S., Ma, L., & Zhou, J. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.001 · Cited by 69
“…earlier data from preclinical and clinical studies also indicated that GLP-1 and its analogues had no significant improvement in the glucose levels or body weight (Frandsen et al., 2015; Dejgaard et al., 2016; Dietrich et al., 2016; Zanotto et al., 2017; Zhao et al., 2013; Hernandez et al., 2016).”
Akturk, H. K., Dong, F., Snell-Bergeon, J. K., Karakus, K. E., & Shah, V. N. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231223991 · Cited by 58
Heydarpour, F., Sajadimajd, S., Mirzarazi, E., Haratipour, P., Joshi, T., Farzaei, M. H., Khan, H., & Echeverría, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.498758 · Cited by 62
“Similarly, earlier data from preclinical and clinical studies also indicated that GLP1 and its analogues had no significant improvement in the glucose levels or body weight (Zhao et al., 2013; Frandsen et al., 2015; Dejgaard et al., 2016; Dietrich et al., 2016; Hernández et al., 2016; Zanotto et al., 2017).”
ResultGlucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus
Guyton, J., Jeon, M., & Brooks, A. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz179 · Cited by 55
GLP-1 Agonists in Type 1 Diabetes Mellitus
Janzen, K. M., Steuber, T. D., & Nisly, S. A. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016651279 · Cited by 53
“Drop-out rates as a result of ADRs were similar across all trials, and the difference was not statistically significant when compared with placebo.(26,27) A recently published, double-blinded, randomized, placebo-controlled trial, the Lira-1 study, recruited 100 participants with uncontrolled T1DM (A1C > 8%) who were…”
Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials
Zhao, X., Huang, K., Zheng, M., & Duan, J. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0332-5 · Cited by 49
Dejgaard, T. F., von Scholten, B. J., Christiansen, E., Kreiner, F. F., Bardtrum, L., von Herrath, M., Mathieu, C., Madsbad, S., & ADJUNCT ONE and ADJUNCT TWO Investigators (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14532 · Cited by 48
“As delineated above, it should be noted that several smaller trials have added to the evidence of the effects of liraglutide in people with type 1 diabetes.(11-19) The investigations have unanimously found no major safety concerns, including no increased risk of hypoglycaemia, and a meta-analysis has reported a lower…”
ResultSelf-citationPatoulias, D., Doumas, M. N., Kotsis, V., Stavropoulos, K., Imprialos, K. P., Zografou, I., Petidis, K., Bakatselos, S., & Karagiannis, A. I. (2020) · Current Diabetes Reviews · doi:10.2174/1573399815666190614141918 · Cited by 53
Shao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 46
Frandsen, C. S., Dejgaard, T. F., Andersen, H. U., Holst, J. J., Hartmann, B., Thorsteinsson, B., & Madsbad, S. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12830 · Cited by 40
Self-citationIlkowitz, J. T., Katikaneni, R., Cantwell, M., Ramchandani, N., & Heptulla, R. A. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816647976 · Cited by 39
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Glycemic Management in Adults With Type 1 Diabetes
McGibbon, A., Adams, L., Ingersoll, K. S., Kader, T., & Tugwell, B. D. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.012 · Cited by 58
Adjunctive therapy for glucose control in patients with type 1 diabetes
Harris, K., Boland, C. L., Meade, L. T., & Battise, D. M. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s141700 · Cited by 37
“0001).(48) Two large, longer-term studies, ADJUNCT ONE and TWO, aimed to determine the effects of liraglutide 0.”
BackgroundKobayati, A., Haidar, A., & Tsoukas, M. A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14637 · Cited by 39
“However, liraglutide resulted in a few more reports of gastrointestinal discomfort compared to placebo.(31) The Lira-1 trial investigated once-daily liraglutide 1.”
Schmidt, S., Frandsen, C. S., Dejgaard, T. F., Vistisen, D., Halldórsson, T., Olsen, S. F., Jensen, J. B., Madsbad, S., Andersen, H. U., & Nørgaard, K. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14567 · Cited by 29
Self-citationLangmach Wegeberg, A., Hansen, C. S., Farmer, A. D., Karmisholt, J. S., Drewes, A. M., Jakobsen, P. E., Brock, B., & Brock, C. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620925968 · Cited by 28
“The postprandial fullness subscale encompasses stomach fullness, early satiety, loss of appetite and postprandial fullness, contributing to decreased appetite, which is a well-known effect of liraglutide.(6,7) The effect has been attributed to centrally mediated appetite regulation effects, such as through the vagal n…”
BackgroundDejgaard, T. F., Frandsen, C. S., Kielgast, U., Størling, J., Overgaard, A. J., Svane, M. S., Olsen, M. H., Thorsteinsson, B., Andersen, H. U., Krarup, T., et al. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15889 · Cited by 29
Self-citationBaylan, U., Korn, A., Emmens, R. W., Schalkwijk, C. G., Niessen, H. W. M., Krijnen, P. A. J., & Şimşek, S. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13807 · Cited by 26
Incretin-based therapies for patients with type 1 diabetes: a meta-analysis
Liu, L., Shao, Z., Xia, Y., Qin, J., Xiao, Y., Zhou, Z., & Mei, Z. (2019) · Endocrine Connections · doi:10.1530/ec-18-0546 · Cited by 26
Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes
Dejgaard, T. F., Johansen, N. B., Frandsen, C. S., Asmar, A., Tarnow, L., Knop, F. K., Madsbad, S., & Andersen, H. U. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12841 · Cited by 26
“The increase in heart rate is in accordance with previous investigations of liraglutide treatment in type 1 and type 2 diabetes.(10,11) Whether this increase represents a mechanism compensatory to reduction in systolic blood pressure via baroreceptor activation,(12) a direct stimulation via cardiac GLP-1 receptors in…”
ResultSelf-citationMetabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?
Warnes, H., Helliwell, R., Pearson, S. M., & Ajjan, R. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0496-z · Cited by 27
Tandon, S., Ayis, S. A., Hopkins, D. L., Harding, S., & Stadler, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14221 · Cited by 32
Kim, Y. J., Hwang, S. D., & Lim, S. K. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00553 · Cited by 24
Harris, K. B., & Boland, C. L. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1804 · Cited by 23
“2 mg/day or placebo for 12 weeks.(25) Liraglutide was titrated from 0.”
MethodJohansen, N. J., Dejgaard, T. F., Lund, A., Schlüntz, C., Hartmann, B., Holst, J. J., Vilsbøll, T., Andersen, H. U., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14568 · Cited by 23
Self-citationFuselier, T. T., de Sa, P. M., Qadir, M. M. F., Xu, B., Allard, C., Meyers, M. M., Tiano, J. P., Yang, B. S., Gelfanov, V. M., Lindsey, S. H., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100598 · Cited by 25
Liraglutide for treating type 1 diabetes
Dejgaard, T. F., Frandsen, C. S., Holst, J. J., & Madsbad, S. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1160050 · Cited by 22
“Patients with type 2 diabetes are more likely than those with type 1 diabetes to be overweight or obese and differences in body weight may explain, at least in part, the higher frequency of GI symptoms in lean patients with type 1 diabetes, who are likely to have a smaller volume of distribution than patients with typ…”
BackgroundMethodInfluentialSelf-citationGlucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?
Resnick, O., Bril, F., & Beauchamp, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1520313 · Cited by 25
Pharmacologic treatment options for type 1 diabetes: what’s new?
Nally, L. M., Sherr, J. L., Name, M. A. V., Patel, A., & Tamborlane, W. V. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1597705 · Cited by 26
“Liraglutide [48,49,63] Weight reduction, lower TDD insulin Obese/overweight patients with T1D Use with caution in patients with thyroid cancer, may cause hemorrhagic or necrotizing pancreatitis, may need to decrease insulin doses to avoid hypoglycemia Nausea, diarrhea, vomiting, decreased appetite, dyspepsia, constipa…”
BackgroundAdjunct therapies in treatment of type 1 diabetes
Goyal, I., Sattar, A., Johnson, M., & Dandona, P. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13078 · Cited by 18
Wang, W., Gao, Y., Chen, D., Wang, C., Feng, X., & Ran, X. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.05.007 · Cited by 19
Kuhadiya, N. D., Prohaska, B. D., Ghanim, H., & Dandona, P. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13609 · Cited by 19
Non-insulin pharmacological therapies for treating type 1 diabetes
Frandsen, C. S., Dejgaard, T. F., Madsbad, S., & Holst, J. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1483339 · Cited by 18
Self-citationDoggrell, S. A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1519547 · Cited by 16
Cardiovascular risk management in type 1 diabetes
Teoh, I. H., Elisaus, P., & Schofield, J. D. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01400-9 · Cited by 15
Karakasis, P., Koufakis, T., Patoulias, D., Barkas, F., Klisic, A. N., Mitrović, M., Doumas, M. N., Παπάνας, Ν., & Popovic, D. S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15979 · Cited by 20
Adjuvant Pharmacotherapies to Insulin for the Treatment of Type 1 Diabetes
Tosur, M., REDONDO, M. J., & Lyons, S. K. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1041-1 · Cited by 15
Double Diabetes: A Growing Problem Requiring Solutions
Popovic, D. S., & Παπάνας, Ν. (2021) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1392-0590 · Cited by 14
Recent developments in adjunct therapies for type 1 diabetes
Timmons, J. G., Littlejohn, L., Boyle, J. G., & Petrie, J. R. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2159806 · Cited by 17
Albèr, A., Brønden, A., & Knop, F. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12911 · Cited by 14
Mader, J. K., Jensen, L., Ingwersen, S. H., Christiansen, E., Heller, S. R., & Pieber, T. R. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0413-4 · Cited by 14
Johansen, N. J., Dejgaard, T. F., Lund, A., Schlüntz, C., Larsen, E. L., Poulsen, H. E., Goetze, J. P., Møller, H. J., Vilsbøll, T., Andersen, H. U., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14078 · Cited by 14
“0 kg/m(2).(10) However, a 5kg/m(2) lower baseline BMI compared to our trial and only 12 weeks' intervention complicate comparisons.”
BackgroundSelf-citationIncretins beyond type 2 diabetes
Mathieu, C., & Ahmadzai, I. (2023) · Diabetologia · doi:10.1007/s00125-023-05980-x · Cited by 17
Lin, C., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · BMC Medicine · doi:10.1186/s12916-020-01787-4 · Cited by 12
Insulin’s Role in Diabetes Management: After 90 Years, Still Considered the Essential “Black Dress”
Cefalu, W. T., Rosenstock, J., LeRoith, D., & Riddle, M. C. (2015) · Diabetes Care · doi:10.2337/dci15-0023 · Cited by 10
Zenz, S., Regittnig, W., Boulgaropoulos, B., Augustin, T., Brunner, M., Korsatko, S., Münzker, J., Narath, S. H., Raml, R., Magnes, C., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac369 · Cited by 11
Aberer, F., Pieber, T. R., Eckstein, M. L., Sourij, H., & Moser, O. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061180 · Cited by 12
“Liraglutide 12 2824 2015 869 2015 (2×) [60,61], 2016 (3×) [62–64], 2018 (2×) [65], 2019 (2×) [66,67], 2020 [68], 2021(2×) [69,70] Figure 1.”
Ang, K. H., & Sherr, J. L. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1360862 · Cited by 11
The effects of GLP-1 agonists on HbA1c and insulin dose among patients with type 1 diabetes
Alhowiti, A., & Mirghani, H. O. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1550938 · Cited by 10
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_20-1 · Cited by 9
Self-citationLamaro, B. D., Greenfield, J. R., & SNAITH, J. R. (2024) · Journal of Patient Experience · doi:10.1177/23743735241257811 · Cited by 10
A Pair of Siblings With Wolfram Syndrome: A Review of the Literature and Treatment Options
Png, D., Yeoh, E. C. K., Tan, C., & Lim, S. C. (2023) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096221150631 · Cited by 9
The changing therapeutic armamentarium for patients with type 1 diabetes
Comee, M., & Peters, A. L. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000239 · Cited by 6
Use of GLP-1 Receptor Agonists for the Management of Type 1 Diabetes: A Pediatric Perspective
Nevo-Shenker, M., & Shalitin, S. (2024) · Hormone Research in Paediatrics · doi:10.1159/000541228 · Cited by 9
“Of note, there was no correlation between starting BMI and the change in body weight [37].”
Rebelos, E., Anastasiou, I. A., Tentolouris, N., Karagiannis, T., Τσάπας, Α., Ferrannini, E., & Liakos, A. (2025) · HORMONES · doi:10.1007/s42000-025-00704-9 · Cited by 8
“Thirteen studies with 2882 patient reported the number of patients with at least one episode of severe hypoglycemia [18, 21–24, 26–28, 30, 34–36, 40].”
InfluentialEncapsulation Strategies for Pancreatic Islet Transplantation without Immune Suppression
Sittadjody, S., & Opara, E. C. (2021) · Current Stem Cell Reports · doi:10.1007/s40778-021-00190-w · Cited by 7
Rizzo, M., Rizvi, A. A., & Sesti, G. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12883 · Cited by 6
“In T2DM, exenatide significantly improved arterial stiffness,11,12 while liraglutide did not.12,13 Similarly, Dejgaard et al.5 report a non- significant effect of liraglutide on arterial stiffness in patients with T1DM.”
InfluentialNoninsulin Therapies in Management of Type 1 Diabetes
Saeed, Z. I., Ambalavanan, J., Rayan, M. N., Patadia, P., & Shah, V. N. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.06.027 · Cited by 7
A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus
AlHabeeb, W., Elasfar, A., Kinsara, A. J., Aljizeeri, A. H., Jelaidan, I., Alghalayini, K. W., AlKheraiji., M. F., Akbar, M. A. J., Lawand, S., Alyousif, S. M., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1407 · Cited by 11
Garg, S., Kim, S., Ford, A. M., Loesch, J., Valencia, S. O., Zhou, K., & Lembo, A. J. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251403555 · Cited by 7
“12 However, recent retrospective real-world studies in 2024 found that semaglutide and tirzepatide in OW/OB adults with T1D were effective in lowering body weight and improving glucose metrics.”
Abdel‐Rahman, S. M., Al-Shiab, R., Shah, E., Güldan, M., Ak, A. B., Yilmaz, Z. Y., Fidan, D. G., Özbek, L., & Kanbay, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70506 · Cited by 7
Johansen, N. J., Dejgaard, T. F., Lund, A., Vilsbøll, T., Andersen, H. U., & Knop, F. K. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-021861 · Cited by 3
Self-citationFuselier, T. T., de Sa, P. M., Qadir, F., Xu, B., Allard, C., Meyers, M., Tiano, J. P., Yang, B. S., Gelfanov, V. M., DiMarchi, R. D., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4009228 · Cited by 3
Lisco, G., Tullio, A. D., Disoteo, O., Armigliato, M., Guastamacchia, E., Marucci, S., Pergola, G. D., Papini, E., Chianelli, M., Frasoldati, A., et al. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70073 · Cited by 2
Mirghani, H. O., Albishi, L. A., & Alblewi, S. M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1758755 · Cited by 2
Dreyer, M. A. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0112-7 · Cited by 2
“[6] mit 40 normalgewichtigen (imMittel 76 kg, BMI 24 kg/m2), schlecht einge-”
den Mooter, L. V., Caerels, S., & Mathieu, C. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1450387 · Cited by 2
Role of Noninsulin Therapies in the Treatment of Type 1 Diabetes
Lingow, S. E., Burke, S. D., Brooks, A. D., & Rafferty, P. S. (2018) · Diabetes Spectrum · doi:10.2337/ds18-0058 · Cited by 2
Yamada, T., Mori, R., Hosoe, J., Shojima, N., Kamata, R., Ishinohachi, K., Yamauchi, T., Tanikawa, Y., & Kadowaki, T. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013164 · Cited by 2
Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes?
Aeng, E. S. Y., Boucher, M., & Severn, M. (2016) · Cited by 2
Therapy of Type 1 Diabetes Mellitus
Omura, E., Cohan, P., & Peters, A. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-20797-1_43-2 · Cited by 1
Ning, X., Munir, K. M., & Davis, S. N. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2439501 · Cited by 2
“No significant change in HbA1c was demonstrated [26].”
Al‐Ozairi, E., Al-Awadi, A. A., Taghadom, E., Kandari, J. A., Alsaeed, D., ALGHANIM, S., Mashankar, A., & le Roux, C. W. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-117431 · Cited by 1
“18 19 The concerns of semaglutide and tirzepatide worsening retinopathy appear only to relate to patients with type 2 diabetes with established pre-proliferative or proliferative retinopathy who then have dramatic improvements in glycaemic control.”
Lawaetz, T. W. H., Kücük, Z., Andersen, T. H., Jensen, A. K., & Johannesen, J. (2025) · Pediatric Diabetes · doi:10.1155/pedi/1633755 · Cited by 2
“…beta cell mass with increased disease duration the add-on of GLP-1 RA might have limited effect on longstanding T1D with low c-peptide levels [39 – 42] and might only be bene fi cial for the patients being early in their disease progression as these patients might still have receptor expression,…”
Zinych, О. В., Kushnariova, N. M., Ковальчук, А., Prybila, O. V., Shyshkan-Shyshova, К. О., Gurina, N. M., & Korpachev, V. V. (2016) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.7.79.2016.86417 · Cited by 1
Leslie, R. D., Pozzilli, P., Peters, A. L., Buzzetti, R., Shankar, S. S., Miličević, Z., Pavo, I. J., Lebrec, J., Martin, S., & Schloot, N. C. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13366 · Cited by 1
“in which they studied the response of a cohort of 19 patients with adult-onset diabetes who were glutamic acid decarboxylase autoantibodies (GADA) positive, most with very low levels of C peptide and multiple autoantibodies, is consistent with published results studying GLP-1 agonists in patients with established type…”
ResultRole of Glucagon-like peptide-1 “Liraglutide” in Management of Type 1 Diabetes
Sehly, A. J. A., Altemani, R. F. H., Alharthi, Y. H. J., Alhwiti, A. G. S., Bedaiwi, A. A. A., Alqulayti, W. M., Alshuwaier, R. A. I., Alaql, A., & Ajwah, I. (2021) · International Journal of Pharmaceutical and Phytopharmacological Research · doi:10.51847/skbdqro7ng
Therapy of Type 1 Diabetes Mellitus
Omura, E., & Peters, A. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_43-1
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_20 · Cited by 1
Self-citationTherapy of Type 1 Diabetes Mellitus
Omura, E., Cohan, P., & Peters, A. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_43
Glucagon Like Peptide-1: More than Glucose Control and Weight ReductionPreprint
Chen, Y., Shao, S., Zhang, X., Xu, Q., & Pan, R. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4161722
León, J. S. T., Dulcey, L., Badillo, L. Y. E., Anaya, S. J. N., Cardenas, R. C. M., & Ávila, H. X. T. (2023) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v7i1.4380
Heald, A. H., Warner-Levy, J. J., Belston, L., Habte‐Asres, H. H., Horne, L., Metters, A., Whyte, M., & Gibson, M. (2023) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000293
Stopyra, M., Feret, K., Andrzejczyk, A., Nafalska, N., Tomaszewska, A., Gadzinowska, J., Kokoszka, M., Chodór, M., Szpila, G., & Lewandowska, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3970
Metadata
- Authors
- Frandsen, C. S., Dejgaard, T. F., Holst, J. J., Andersen, H. U., Thorsteinsson, B., & Madsbad, S.
- Affiliations
- University of Copenhagen (DK)
- Steno Diabetes Center, Gentofte, Denmark
- Corresponding author
- Frandsen, Christian S.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-10-20
- Volume
- 38
- Issue
- 12
- Pages
- 2250-2257
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1806569300
- Cited by
- 103
- References
- 40
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 8 · 2023: 6 · 2022: 9 · 2021: 8 · 2020: 9 · 2019: 7 · 2018: 15 · 2017: 8 · 2016: 16 · 2015: 2
- FWCI
- 11.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Funders
- The Danish School of Metabolism and Endocrinology
- Novo Nordisk Foundation, Center for Basic Metabolic Research
- The Research Foundation at Hvidovre University Hospital
- The Beckett Foundation,
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- liraglutide, type 1 diabetes, insulin add-on therapy, normal-weight patients, glycemic control, HbA1c, glycemic excursions, weight loss, heart rate, blood pressure, gastrointestinal adverse effects, GLP-1 receptor agonists, continuous glucose monitoring, drug safety and tolerability, uncontrolled diabetes
- MeSH terms
- Liraglutide, Adult, Body Weight, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hypoglycemic Agents, Insulin, Male, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.